I imagine Kat Charles' tumour was probably mutated IDH, given her young age and the fact that it was a secondary GBM. I also imagine that she is glad she found DCVax-L rather than pursue a different option.
When did Liau and Prins suggest that L may be less effective with this classification? What lead them to make that conclusion?
Kat is only one case of course, but I don't know what else it could have been that afforded her long-term remission, other than the DCVax-L that she received.
I'm not aware of anything to suggest that L is less effective with other high grade gliomas. It's just that there hasn't been a formal trial. I know that L was only used in a handful of patients under the German Hospital Exemption scheme, but that exemption was for all gliomas. And I imagine that there is nothing to prevent L being used for IDH mutation under UK Specials, if the referring specialist believes it to be the best treatment option.
Market Data 
Markets 
AI
